【摘要】 目的探讨乳腺癌术后接受EC-T方案化疗患者放疗开始时间对无进展生存期(PFS)的影响。方法回顾性分析芜湖市第二人民医院2015年1月至2018年3月收治的80例乳腺癌术后患者资料,按手术到放疗间隔时间(SRI)分为两组,A组(SRI≤6个月)31例和B组(6个月<SRI<8个月)49例,均行EC-T方案辅助化疗及术后辅助放疗。对比两组患者随访2年内局部复发率、远处转移率及PFS。结果两组年龄、月经状态、肿瘤大小、靶向治疗、肿瘤数量、分子分型、淋巴结分期、化疗期间3～4级不良反应发生情况、放疗并发症发生率,差异均无统计学意义(均P>005)。两组患者术后2年复发率、转移率以及两组的PFS差异也均无统计学意义(均P>005)。多因素Cox比例风险模型分析结果显示,分子分型、肿瘤大小、淋巴结分期是PFS的独立影响因素(P<005)。结论乳腺癌术后EC-T化疗序贯放疗,SRI不超过8个月并不影响患者的远期生存率。更多还原

【Abstract】 Objective To investigate the effect of radiotherapy start time on progression-free survival(PFS) in patients undergoing EC-T chemotherapy after breast cancer surgery.Methods Clinical data of 80 postoperative breast cancer patients was analyzed retrospectively who were admitted to the Second Peoples Hospital of Wuhu City from January 2015 to March 2018 and divided into group A(SRI≤6 months, 31 patients)and group B(SRI 6-8 months, 49 patients). All the patients accepted EC-T regimen after adjuvant chemotherapy and postoperative adjuvant radiotherapy. The incidences of local recurrence and distant metastasis as well as PFS were compared between the two groups in 2 years of follow-up.Results There was no significant difference in age, menstrual status, tumor size, targeted therapeutic regimen, the number of tumor, molecular subtyping, lymph node stage, adverse reactions of chemotherapy with grade 3-4, and radiotherapy complications between the two groups(P>0 05). There was no statistically significant difference in the two-year relapse, metastasis rate and PFS between the two groups(P>0 05). The results of multi-factor Cox proportional hazards model analysis showed that molecular classification, tumor size, and lymph node stage were independent influencing factors for PFS(P<0 05), but not the start time of radiotherapy(P>0 05).Conclusions For patients undergoing EC-T chemotherapy after breast cancer surgery, the duration from surgery to radiotherapy for more than 6 months may not affect long-term survival and progression.更多还原